David Westenberg
Stock Analyst at Piper Sandler
(4.66)
# 179
Out of 5,055 analysts
187
Total ratings
60.38%
Success rate
22.78%
Average return
Main Sectors:
Stocks Rated by David Westenberg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TXG 10x Genomics | Maintains: Neutral | $15 → $19 | $15.89 | +19.57% | 3 | Nov 11, 2025 | |
| TEM Tempus AI | Maintains: Neutral | $105 → $80 | $68.48 | +16.82% | 6 | Nov 11, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Neutral | $1.5 → $2 | $1.61 | +24.22% | 10 | Nov 11, 2025 | |
| NTRA Natera | Maintains: Overweight | $220 → $230 | $204.28 | +12.59% | 17 | Nov 11, 2025 | |
| FLGT Fulgent Genetics | Maintains: Neutral | $21 → $30 | $29.10 | +3.09% | 10 | Nov 11, 2025 | |
| EXAS Exact Sciences | Maintains: Overweight | $70 → $80 | $67.03 | +19.35% | 13 | Nov 11, 2025 | |
| CTKB Cytek Biosciences | Maintains: Overweight | $8 → $7.5 | $5.50 | +36.36% | 10 | Nov 11, 2025 | |
| DGX Quest Diagnostics | Maintains: Neutral | $190 → $200 | $186.95 | +6.98% | 8 | Oct 27, 2025 | |
| GH Guardant Health | Maintains: Overweight | $60 → $90 | $94.37 | -4.63% | 10 | Oct 22, 2025 | |
| NEOG Neogen | Reiterates: Neutral | $5 → $6.5 | $6.39 | +1.72% | 13 | Oct 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $20 | $14.10 | +41.84% | 15 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $140 | $128.06 | +9.32% | 3 | Sep 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $210 → $215 | $120.82 | +77.95% | 15 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $510 → $700 | $689.93 | +1.46% | 11 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $12 → $18 | $21.09 | -14.65% | 10 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $11 | $10.34 | +6.38% | 10 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $190 → $185 | $120.67 | +53.31% | 16 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $260 → $280 | $266.89 | +4.91% | 4 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $21.34 | - | 2 | Jan 4, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $37.74 | - | 1 | Nov 21, 2017 |
10x Genomics
Nov 11, 2025
Maintains: Neutral
Price Target: $15 → $19
Current: $15.89
Upside: +19.57%
Tempus AI
Nov 11, 2025
Maintains: Neutral
Price Target: $105 → $80
Current: $68.48
Upside: +16.82%
Pacific Biosciences of California
Nov 11, 2025
Maintains: Neutral
Price Target: $1.5 → $2
Current: $1.61
Upside: +24.22%
Natera
Nov 11, 2025
Maintains: Overweight
Price Target: $220 → $230
Current: $204.28
Upside: +12.59%
Fulgent Genetics
Nov 11, 2025
Maintains: Neutral
Price Target: $21 → $30
Current: $29.10
Upside: +3.09%
Exact Sciences
Nov 11, 2025
Maintains: Overweight
Price Target: $70 → $80
Current: $67.03
Upside: +19.35%
Cytek Biosciences
Nov 11, 2025
Maintains: Overweight
Price Target: $8 → $7.5
Current: $5.50
Upside: +36.36%
Quest Diagnostics
Oct 27, 2025
Maintains: Neutral
Price Target: $190 → $200
Current: $186.95
Upside: +6.98%
Guardant Health
Oct 22, 2025
Maintains: Overweight
Price Target: $60 → $90
Current: $94.37
Upside: -4.63%
Neogen
Oct 16, 2025
Reiterates: Neutral
Price Target: $5 → $6.5
Current: $6.39
Upside: +1.72%
Oct 15, 2025
Maintains: Overweight
Price Target: $15 → $20
Current: $14.10
Upside: +41.84%
Sep 11, 2025
Maintains: Overweight
Price Target: $120 → $140
Current: $128.06
Upside: +9.32%
Aug 11, 2025
Maintains: Overweight
Price Target: $210 → $215
Current: $120.82
Upside: +77.95%
Aug 11, 2025
Maintains: Neutral
Price Target: $510 → $700
Current: $689.93
Upside: +1.46%
Aug 11, 2025
Maintains: Neutral
Price Target: $12 → $18
Current: $21.09
Upside: -14.65%
Aug 4, 2025
Maintains: Overweight
Price Target: $12 → $11
Current: $10.34
Upside: +6.38%
May 15, 2025
Maintains: Overweight
Price Target: $190 → $185
Current: $120.67
Upside: +53.31%
May 6, 2025
Maintains: Neutral
Price Target: $260 → $280
Current: $266.89
Upside: +4.91%
Jan 4, 2018
Upgrades: Buy
Price Target: n/a
Current: $21.34
Upside: -
Nov 21, 2017
Initiates: Neutral
Price Target: n/a
Current: $37.74
Upside: -